Zoey Tang

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐ DXd ), a TROP2 ‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

Ying Hong, Anna M. Mc Laughlin, Yuzhuo Pan, Sofia Friberg Hietala et autres

Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior therapies. Exposure‐response (ER) analyses were conducted using Phase 1–3 clinical data from patients with NSCLC (efficacy and …

us, nl, pl, br, jp (code pays fourni par la source)

Supplementary Table S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

Supplementary Table S4. Baseline patient demographics and disease characteristics of patients receiving single-agent volrustomig 750 mg in the parallel phase I study in Japanese patients.

Supplementary Figure S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

Supplementary Figure S4. Molecular response dynamics (ctDNA) across all dose levels (225–2500 mg). Percent change from baseline in mVAF up to week 6.

Supplementary Figure S2 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

Supplementary Figure S2. PD-1 receptor occupancy on CD8+ T cells over time.

Supplementary Figure S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

Supplementary Figure S5. Mean volrustomig plasma concentration over time during cycle 1 in patients (n = 6) in the phase 1 study in Japanese patients.

Supplementary Methods S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

Supplementary Methods

Supplementary Table S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

Supplementary Table S5. Safety profile and TRAEs in patients receiving volrustomig 750 mg in the parallel phase I study in Japanese patients.

Supplementary Table S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

Supplementary Table S1. Representativeness of study participants.

Supplementary Figure S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

Supplementary Figure S1. Study design – dose exploration and dose expansion with volrustomig IV Q3W.

Supplementary Figure S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

Supplementary Figure S3. Kaplan–Meier analysis of DoR in patients who had an objective response to volrustomig IV Q3W in the dose-exploration and 2000 mg expansion cohorts.

Supplementary Table S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

Supplementary Table S3. Preliminary efficacy of single-agent volrustomig in the modified response-evaluable population/efficacy analysis set in the individual dose-exploration cohorts.

Data from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

AbstractPurpose: Volrustomig is an IgG1 monovalent bispecific antibody engineered to preferentially target cytotoxic T lymphocyte–associated antigen-4 (CTLA-4) on programmed cell death protein 1 (PD-1)–positive T cells while providing adequate and durable PD-1 inhibition. The aim of this phase I, first-in-human study (NCT03530397) …